Annual Cash & Cash Equivalents
$3.13 M
-$2.23 M-41.63%
01 December 2023
Summary:
NovaBay Pharmaceuticals annual cash & cash equivalents is currently $3.13 million, with the most recent change of -$2.23 million (-41.63%) on 01 December 2023. During the last 3 years, it has fallen by -$4.37 million (-58.29%). NBY annual cash & cash equivalents is now -75.42% below its all-time high of $12.73 million, reached on 31 December 2012.NBY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$776.00 K
+$25.00 K+3.33%
01 September 2024
Summary:
NovaBay Pharmaceuticals quarterly cash and cash equivalents is currently $776.00 thousand, with the most recent change of +$25.00 thousand (+3.33%) on 01 September 2024. Over the past year, it has dropped by -$2.35 million (-75.21%). NBY quarterly cash and cash equivalents is now -94.21% below its all-time high of $13.41 million, reached on 30 September 2020.NBY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBY Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -75.2% |
| 3 y3 years | -58.3% | -89.7% |
| 5 y5 years | -54.9% | -88.8% |
NBY Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -58.3% | at low | -89.7% | +3.3% |
| 5 y | 5 years | -73.8% | at low | -94.2% | +3.3% |
| alltime | all time | -75.4% | +41.8% | -94.2% | +12.6% |
NovaBay Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $776.00 K(+3.3%) |
| June 2024 | - | $751.00 K(-58.8%) |
| Mar 2024 | - | $1.82 M(-41.8%) |
| Dec 2023 | $3.13 M(-41.6%) | $3.13 M(-9.9%) |
| Sept 2023 | - | $3.47 M(-21.3%) |
| June 2023 | - | $4.41 M(+17.8%) |
| Mar 2023 | - | $3.75 M(-30.1%) |
| Dec 2022 | $5.36 M(-28.5%) | $5.36 M(+38.6%) |
| Sept 2022 | - | $3.87 M(-1.6%) |
| June 2022 | - | $3.93 M(-30.3%) |
| Mar 2022 | - | $5.64 M(-24.8%) |
| Dec 2021 | $7.50 M(-37.2%) | $7.50 M(-16.9%) |
| Sept 2021 | - | $9.03 M(-12.3%) |
| June 2021 | - | $10.29 M(-2.0%) |
| Mar 2021 | - | $10.51 M(-12.1%) |
| Dec 2020 | $11.95 M(+72.3%) | $11.95 M(-10.9%) |
| Sept 2020 | - | $13.41 M(+52.9%) |
| June 2020 | - | $8.78 M(+53.7%) |
| Mar 2020 | - | $5.71 M(-17.7%) |
| Dec 2019 | $6.94 M(+117.9%) | $6.94 M(-23.1%) |
| Sept 2019 | - | $9.02 M(+145.9%) |
| June 2019 | - | $3.67 M(+25.1%) |
| Mar 2019 | - | $2.93 M(-7.9%) |
| Dec 2018 | $3.18 M(-0.5%) | $3.18 M(-38.9%) |
| Sept 2018 | - | $5.21 M(-23.8%) |
| June 2018 | - | $6.83 M(-18.0%) |
| Mar 2018 | - | $8.34 M(+160.6%) |
| Dec 2017 | $3.20 M(-66.4%) | $3.20 M(-47.4%) |
| Sept 2017 | - | $6.08 M(+6.2%) |
| June 2017 | - | $5.72 M(-22.7%) |
| Mar 2017 | - | $7.40 M(-22.2%) |
| Dec 2016 | $9.51 M(+298.8%) | $9.51 M(+0.9%) |
| Sept 2016 | - | $9.43 M(+169.8%) |
| June 2016 | - | $3.50 M(+144.4%) |
| Mar 2016 | - | $1.43 M(-40.0%) |
| Dec 2015 | $2.38 M | $2.38 M(-29.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $3.38 M(-53.1%) |
| June 2015 | - | $7.21 M(+28.8%) |
| Mar 2015 | - | $5.60 M(+3.1%) |
| Dec 2014 | $5.43 M(-48.3%) | $5.43 M(-31.1%) |
| Sept 2014 | - | $7.88 M(+1.6%) |
| June 2014 | - | $7.76 M(-24.8%) |
| Mar 2014 | - | $10.32 M(-1.8%) |
| Dec 2013 | $10.50 M(-17.6%) | $10.50 M(+51.4%) |
| Sept 2013 | - | $6.93 M(+5.2%) |
| June 2013 | - | $6.59 M(-21.4%) |
| Mar 2013 | - | $8.39 M(-34.1%) |
| Dec 2012 | $12.73 M(+51.1%) | $12.73 M(+76.4%) |
| Sept 2012 | - | $7.22 M(+55.1%) |
| June 2012 | - | $4.65 M(-24.0%) |
| Mar 2012 | - | $6.12 M(-27.4%) |
| Dec 2011 | $8.43 M(-26.9%) | $8.43 M(-32.2%) |
| Sept 2011 | - | $12.43 M(+55.9%) |
| June 2011 | - | $7.97 M(-32.8%) |
| Mar 2011 | - | $11.87 M(+2.9%) |
| Dec 2010 | $11.53 M(+4.9%) | $11.53 M(+22.5%) |
| Sept 2010 | - | $9.41 M(-9.0%) |
| June 2010 | - | $10.34 M(-19.8%) |
| Mar 2010 | - | $12.89 M(+17.3%) |
| Dec 2009 | $10.99 M(-9.1%) | $10.99 M(+3.4%) |
| Sept 2009 | - | $10.63 M(+32.9%) |
| June 2009 | - | $8.00 M(-21.9%) |
| Mar 2009 | - | $10.24 M(-15.3%) |
| Dec 2008 | $12.10 M(+10.6%) | $12.10 M(+3.1%) |
| Sept 2008 | - | $11.74 M(+17.4%) |
| June 2008 | - | $10.00 M(-11.6%) |
| Mar 2008 | - | $11.31 M(+3.4%) |
| Dec 2007 | $10.94 M(+123.1%) | $10.94 M(+1488.0%) |
| Sept 2007 | - | $689.00 K(-63.2%) |
| June 2007 | - | $1.87 M(-51.5%) |
| Mar 2007 | - | $3.86 M(-21.3%) |
| Dec 2006 | $4.90 M(+122.1%) | $4.90 M(+122.1%) |
| Dec 2005 | $2.21 M | $2.21 M |
FAQ
- What is NovaBay Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is NovaBay Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of NBY is $3.13 M
What is the all time high annual cash & cash equivalents for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high annual cash & cash equivalents is $12.73 M
What is NovaBay Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NBY is $776.00 K
What is the all time high quarterly cash and cash equivalents for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high quarterly cash and cash equivalents is $13.41 M
What is NovaBay Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, NBY quarterly cash and cash equivalents has changed by -$2.35 M (-75.21%)